FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc (PSNL). (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study ...

Cervical cancer remains one of the most challenging diseases in oncology, with high recurrence rates and significant treatment side effects. For decades, the standard approach has relied on a ...

Tivdak is a tissue factor-directed antibody and microtubule inhibitor conjugate. The Food and Drug Administration (FDA) has granted full approval to Tivdak ® (tisotumab vedotin-tftv) for the treatment ...

Cervical cancer is a serious type of cancer and its recurrence after treatment is an issue doctors want to address. Experts are interested in finding the best combination of therapies to treat ...

The US Food and Drug Administration (FDA) has approved the checkpoint inhibitor pembrolizumab (Keytruda, Merck) alongside standard chemotherapy — with or without bevacizumab — as first-line therapy ...

A new computer model may be able to forecast cervical cancer recurrence in an individual based on how the tumor changes in size after the first rounds of radiation therapy, a team of researchers ...

Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 ...

This study, innovaTV 301, was a phase 3, multinational, open-label trial (n = 502) of tisotumab vedotin as a second- or third-line therapy compared with the investigator's choice of chemotherapy. The ...

Top line data show that the randomized Phase II study of TG4001 in combination with avelumab versus avelumab alone in patients with recurrent or metastatic HPV16-positive cervical and anogenital ...

Cervical cancer remains a significant health concern, accounting for approximately 4,000 deaths annually in the United States alone. Recent advancements in treatment strategies are crucial, especially ...

Cadonilimab plus platinum-based chemotherapy ± bevacizumab for persistent, recurrent, or metastatic cervical cancer: Subgroup analyses of COMPASSION-16. This is an ASCO Meeting Abstract from the 2025 ...